4 unknown, 1 completed, 1 recruiting, 1 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 4, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Chemotherapeutic Toxicity: new trials by email Literature Review of Chemotherapeutic Toxicity trials Research Report on Chemotherapeutic Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody - Hepatocellular Carcinoma, Chemotherapy Effect | Phase 3 | Recruiting | Sun Yat-sen University | 540 | 2023-10-31 | 2024-08-27 |
| The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis a compound glutamine capsule/a compound glutamine capsule simulated placebo - Mucositis, Chemotherapeutic Toxicity | Phase 3 | Unknown | Meng Qiu | 108 | 2021-06-30 | 2021-10-25 |
| The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis a compound glutamine capsule, a compound glutamine capsule simulated placebo - Mucositis, Chemotherapeutic Toxicity | Phase 3 | Unknown | Meng Qiu | 90 | 2021-06-30 | 2021-10-15 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Trilaciclib, Placebo - Colorectal Cancer Metastatic, Myelosuppression-Adult | Phase 3 | Terminated | G1 Therapeutics, Inc. | 326 | 2021-01-06 | 2024-11-26 |
| Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy Gabapentin 300mg - Invasive Breast Cancer, Chemotherapeutic Toxicity | Phase 2 / Phase 3 | Unknown | British Columbia Cancer Agency | 46 | 2018-07-02 | 2018-06-25 |
| Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC Docetaxel, Oxaliplatin, Cisplatin - Stomach Neoplasms, Chemotherapy Effect | Phase 3 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 240 | 2013-04-01 | 2017-09-15 |
| Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® LA-EP2006, Neulasta® - Neutropenic Complications, Breast Neoplasms | Phase 3 | Completed | Sandoz | 316 | 2012-06-01 | 2017-08-07 |
Mucositis (2) · Arthralgia (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Myalgia (1) · Neutropenia (1) · Stomach Neoplasms (1)
Digestive System Diseases (5) · Gastrointestinal Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Digestive System Neoplasms (3) · Gastroenteritis (2) · Gastrointestinal Neoplasms (2) · Mouth Diseases (2) · Stomatognathic Diseases (2) · Adenocarcinoma (1) · Agranulocytosis (1) · Breast Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Cytopenia (1)
Oxaliplatin (2) · Cisplatin (1) · Docetaxel (1) · Fluorouracil (1) · Gabapentin (1) · Irinotecan (1) · Leucovorin (1) · Pemetrexed (1) · S 1 (combination) (1) · pegfilgrastim (1) · trilaciclib (1)
Meng Qiu (2) · British Columbia Cancer Agency (1) · G1 Therapeutics, Inc. (1) · Sandoz (1) · Sun Yat-sen University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
China (5) · Ukraine (2) · Brazil (1) · Hungary (1) · India (1) · Italy (1) · Mexico (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 12372721, PMID 24293372, PMID 25752327, PMID 27020170, PMID 28637287, PMID 29061175, PMID 29307467, PMID 29471013, PMID 31070690, PMID 32418078, PMID 33538338, PMID 36525610, PMID 39579142